See today's BioWorld Asia
To read the full story, subscribe or sign in.

China’s NMPA approves Junshi’s PCSK9 ongericimab

Oct. 15, 2024
By Tamra Sami
No Comments
China’s National Medical Products Administration has given the thumbs up to Junshi Biosciences Co. Ltd.’s NDA for ongericimab, a recombinant humanized anti-PCSK9 monoclonal antibody, marking the third PCSK9 inhibitor to be cleared in China.
BioWorld Asia Regulatory Cardiovascular Monoclonal antibody Asia-Pacific China NMPA